Document text
Principal Investigator: Rajesh Khanna
Organization: REGULONIX, LLC
Fiscal Year: 2021
Award: $419,470
Funding agency: National Institute of Neurological Disorders and Stroke
ABSTRACT Revisions noted in blue font
First reported in December of 2019, coronavirus disease (COVID-19) has taken the world by storm, exacting a
heavy toll not only in terms of the number of deaths (~1,700,000) it has caused worldwide but also its decimation
of world economies (~$8.8 trillion). Because infection with SARS-CoV-2, the causative agent of COVD-19, can
be spread by asymptomatic, presymptomatic, and symptomatic carriers, the virus has been difficult to contain.
Our preliminary data shows that Spike protein, the major surface antigen of SARS-CoV-2, is analgesic.
Therefore, an explanation for the unabated spread (~77 million infected worldwide as of December 21, 2020)
may be that asymptomatic or presymptomatic individuals do not experience the pain and discomfort that act as
early warning signs of infection. We found that Spike protein binds to a surface receptor called neuropilin 1 (NRP-
1) to allow viral entry into cells. Vascular endothelial growth factor-A (VEGF-A) – a pro-nociceptive and
angiogenic factor, binds NRP-1, and induces mechanical allodynia and thermal hyperalgesia that is blocked by
Spike protein. Pharmacological antagonism of NRP-1 also blocks VEGF-A–induced pain behaviors. These
results identify NRP-1 as a new player in pain. How VEGF-A–activated signaling via NRP-1 leads to pain is an
open question. Leveraging this atypical pain-relieving function of the SARS-CoV-2 Spike interaction with NRP-
1, the laboratory of Dr. Rajesh Khanna (University of Arizona (UA)) performed a virtual screen of nearly 0.5
million compounds (diverse small molecules and commercially available natural products) against the VEGF-A
binding site on the NRP-1 b1 domain. Several of the top 20 ‘hit’ compounds from this screen have been validated
in in vitro and in vivo experiments, providing experimental proof of our in-silico predictions. We have partnered
with Regulonix LLC to test the hypothesis that SARS-CoV-2 Spike protein binding to NRP-1 triggers increases
in sodium and calcium channel activity to increase nociceptor activity culminating in enhanced pain and that this
signaling cascade can be blocked by inhibitors of NRP-1-VEGF-A interaction. Regulonix’s Specific Aims,
guided by quantitative goals, are: (1) to profile NRP-1 targeting compounds for their (i) to ability to bind to NRP-
1; (ii) to block the NRP-1-VEGF-A interaction using ELISA; and (iii) to inhibit VEGF-A mediated increase in
phosphorylation of VEGFR2, a proxy for activation of VEGF-A/NRP-1 signaling. A subset of compounds will be
tested for their ability to inhibit calcium and sodium currents in sensory neurons using whole-cell
electrophysiology with a smaller subset being tested in human DRGs to enhance rigor and the translational utility
of these compounds; (2) Profile NRP-1 targeting compounds for their in vitro cellular cytotoxicity, physico-
chemical, early ADME, and PK properties, and for off-target effects on GPCRs, kinases, ion channels and
alternative known pain targets, including opioid receptors; and (3) Characterize the best 2 NRP-1 targeting
compounds in an acute model of post-surgical pain and in the spared nerve injury (SNI) model of neuropathic
pain. To address safety, a phenotypic screen for motor impairment will be run prior to the SNI model. At the end
of our study, we expect to have validated NRP-1 inhibitors for neuropathic pain. Two compounds will be
evaluated in the ALGOGramTM, a panel of diverse behavioral pain models by an external third-party – ANS
Biotech (Riom, France). Completion of these experiments will characterize the role of NRP-1 as a novel anti-
nociceptive protein and will open opportunities for targeting of NRP-1 for persistent neuropathic pain treatment.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><A5 Antigen><ACE2><Acute><Address><Afferent Neurons><Affinity><American><Analgesic Agents><Analgesic Drugs><Analgesic Preparation><Analgesics><Angiogenesis Factor><Angiogenic Factor><Anodynes><Antinociceptive Agents><Antinociceptive Drugs><Arizona><Assay><Behavioral><Binding><Binding Proteins><Binding Sites><Bioassay><Biologic Assays><Biologic Sciences><Biological Assay><Biological Sciences><Bioscience><Biotech><Biotechnology><COVID><COVID-19><COVID-19 S protein><COVID-19 antigen><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19><COVID19 S protein><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><Calcium><Calcium Channel><Calcium Channel Antagonist Receptor><Calcium Channel Blocker Receptors><Calcium Ion Channels><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Antigens><Cell Surface Receptors><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cells><Cellular Cytotoxicity><Cessation of life><Chemicals><CoV disease><CoV-2><CoV2><Combining Site><Common Rat Strains><Crystallization><Data><Death><Development><Disclosure><Dorsal Root Ganglia><Drug Kinetics><Drugs><ELISA><Electrophysiology><Electrophysiology (science)><Enzyme-Linked Immunosorbent Assay><FLK1><France><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GPCR><Goals><Human><Immunologic Surface Markers><Immunological Surface Markers><In Vitro><Individual><Infection><Information Disclosure><Intracellular Communication and Signaling><Ion Channel><Ionic Channels><KDR gene><Kinases><Laboratories><Lead><Life Sciences><Ligand Binding Protein><Ligand Binding Protein Gene><Lions><Lymphocyte Cytotoxicity><Lymphocytotoxicity><Mediating><Medication><Medicinal Chemistry><Medulla Spinalis><Membrane Channels><Modeling><Modern Man><Molecular><Molecular Interaction><NRP1 Protein><Na element><Natural Products><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><Neurophysiology / Electrophysiology><Neuropilin-1><Nociception><Nociceptors><Npn-1 Protein><Opiate Receptors><Opioid Receptor><Oral><Otomy><Pain><Pain Control><Pain Therapy><Pain management><Painful><Panthera leo><Pathway interactions><Pb element><Pharmaceutic Chemistry><Pharmaceutic Preparations><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacokinetics><Pharmacology><Phenotype><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Post-operative Pain><Postoperative Pain><Property><Protein Binding><Protein Phosphorylation><Proteins><Proxy><Rat><Rats Mammals><Rattus><Reactive Site><Receptor Protein><Recombinants><Reporting><Role><Route><Running><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 antigen><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antigen><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sema III Receptor><Semaphorin III Receptor><Sensory Cell Afferent Neuron><Sensory Neurons><Series><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Sodium><Sodium Channel><Sodium Ion Channels><Specificity><Spinal Cord><Spinal Ganglia><Structure><Surface><Surface Antigens><Surgical incisions><Technology><Testing><Thermal Hyperalgesias><Translating><Transphosphorylases><Universities><VDCC><VEGF><VEGF Receptors><VEGFA><VEGFA gene><VEGFR><VEGFR-2><VEGFR2><VEGFs><VPF Receptor><VSV><Validation><Vascular Endothelial Cell Growth Factor 165 Receptor><Vascular Endothelial Cell Growth Factor Receptor><Vascular Endothelial Growth Factor A><Vascular Endothelial Growth Factor Receptor 2><Vascular Endothelial Growth Factors><Vascular Permeability Factor Receptor><Vasculotropin><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><Voltage-Dependent Calcium Channels><Work><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><biological signal transduction><biophysical characteristics><biophysical characterization><biophysical measurement><biophysical parameters><biophysical properties><bound protein><cell mediated cytotoxicity><chronic neuropathic pain><chronic pain><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antigen><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><design><designing><developmental><dorsal root ganglion><drug candidate><drug discovery><drug/agent><electrophysiological><experiment><experimental research><experimental study><hCoV19><heavy metal Pb><heavy metal lead><in silico><in vivo><incision><inhibitor><inhibitor/antagonist><invention><mechanical allodynia><motor impairment><movement impairment><movement limitation><nCoV2><nerve injury><neural injury><neuronal><neuropathic pain><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><nociceptive><non-narcotic analgesic><non-opiate analgesic><non-opioid><non-opioid analgesic><non-opioid therapeutics><nonnarcotic analgesics><nonopiate analgesic><nonopioid><nonopioid analgesics><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pain after surgery><pain behavior><pain killer><pain medication><pain model><pain relief><pain reliever><pain signal><pain treatment><painful neuropathy><painkiller><pathway><post-surgical pain><postsurgical pain><pre-clinical><pre-clinical study><preclinical><preclinical study><protein protein interaction><receptor><relieve pain><severe acute respiratory syndrome coronavirus 2 antigen><small molecule><small molecule inhibitor><social role><spared nerve><success><uptake><virtual><virus protein>